Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis

Table 1 Demographic, clinical and endoscopic characteristics of the patients and controls

Variable	Patients (n = 122)	Controls (n = 30)
Sex (male/female; %)	55/45	50/50
Age (yr; SD)	51.14 (± 9.73)	48.92 (± 15.46)
BMI (kg/m2; SD)	26.04 (± 4.63)	25.30 (± 3.51)
Etiology (N (%) of patients)
Alcohol induced cirrhosis	61 (50)
HCV cirrhosis	61 (50)
Child-Pugh class (A/B/C; %)	61.5/24.6/13.9
MELD score (SD)	11.15 (± 4.32)
TE (kPa; SD)	31.37 (± 19.79)
Ascites (% of patients)	38.5
Varices (% of patients)
Absent	45.1
F1	27
F2	18.9
F3	9
Risk signs of bleeding (N of patients)	24
HVPG (mmHg; SD)	13.70 (± 6.52)
HVPG 1-5 mmHg (% of patients)	11.5
HVPG 5-9 mmHg (% of patients)	19.7
CSPH; HVPG ≥ 10 mmHg (% of patients)	70.5
SPH; HVPG ≥ 12 mmHg (% of patients)	57.4

SD: Standard deviation; BMI: Body mass index; HCV: Hepatitis C virus; MELD: Model of End Stage Liver Disease; HVPG: Hepatic venous pressure gradient; CSPH: Clinically significant portal hypertension; SPH: Severe portal hypertension; TE: Transient elastography.